Adarza Timeline

6 02, 2020

St. Louis biotech startup raises $25M as it prepares for commercialization

2020-02-06T14:03:46-06:00February 6th, 2020|

Adarza BioSystems said the funding will help it prepare for commercialization of its ZIVA platform, a biological testing device designed to assist researchers with disease profiling and drug development.

5 02, 2020

Adarza raises $25 million, moves toward commercialization

2020-02-06T13:57:15-06:00February 5th, 2020|

Adarza, based in Maryland Heights, makes diagnostic systems for researchers and drug companies. It plans to launch its testing platform commercially in June.

4 02, 2020

Adarza BioSystems Raises $25 Million in Series D Funding to Launch Platform for Research and Drug Development

2020-02-06T13:37:24-06:00February 4th, 2020|

Biotech company Adarza BioSystems announced today that it has raised $25 million in a Series D round co-led by 3x5 Partners, based in Portland, Ore., and St. Louis-based Lightchain Capital, LLC, the family office of Scottrade founder Rodger Riney. Adarza plans to use the funds to support full commercialization of ZIVA, its automated biological testing platform for academic and clinical research. Scheduled for commercial launch in June, the ZIVA platform will allow researchers to quickly identify inflammation, cardiovascular, and oncology protein biomarkers for disease profiling and drug development.

24 01, 2017

St. Louis Business Journal: RiverVest leads $17M investment in Adarza, brings on new president

2017-09-11T12:53:54-05:00January 24th, 2017|

RiverVest leads $17 million investment in Adarza, brings on new president

19 01, 2017

ADARZA BIOSYSTEMS CLOSES ON $17 MILLION SERIES C FINANCING

2018-05-02T01:29:44-05:00January 19th, 2017|

ROCHESTER, NY and ST LOUIS, MO (Jan. 19, 2017) – Adarza BioSystems, Inc., a leading next generation innovator in label-free, multiplex assays, announced today that it has closed a $17M Series C financing. Proceeds from the financing will be used to further expand production capacity in its St. Peters, MO manufacturing facility and fund final development and commercialization of Adarza’s first immunoassay product consumable and instrument platform. Adarza develops and manufactures immunoassay technology that can identify proteins and genetic markers in medical samples such as blood. The technology, which comes in the form of microchips, [...]

24 03, 2016

Adarza BioSystems Completes $5 M Series-B Closing

2018-05-02T01:29:44-05:00March 24th, 2016|

ROCHESTER, N.Y. ST LOUIS, MO – Adarza BioSystems, Inc. a leading next generation innovator in label-free, multiplex assays announced today that it has closed a $5 M Series B financing. Proceeds from the financing will be used to expand production capacity in its St. Peters, MO manufacturing facility and launch its first immunoassay product consumable and instrument platform. Proceeds will also be used to accelerate development of highly sensitive assays targeting a variety of biological analytes including cytokines, antigens and small molecules. Adarza’s Arrayed Imaging Reflectometry (AIRstrip™) will bring an unprecedented combination of performance, [...]

25 11, 2014

Horizon Discovery Group plc and Adarza BioSystems Enter Supply & Licensing Agreement

2018-05-02T01:29:44-05:00November 25th, 2014|

Agreement gives Horizon exclusive right to supply services on Ardaza’s multiplex label-free immunoassay technology.

24 10, 2014

Adarza BioSystems Selects SunEdison Semiconductor Site for Manufacturing Immunoassay Consumables

2018-05-02T01:29:44-05:00October 24th, 2014|

Adarza BioSystems, Inc. has executed an agreement with SunEdison Semiconductor to establish immunoassay consumable manufacturing facilities at its St. Peters, Missouri manufacturing site.

1 10, 2014

Adarza BioSystems Completes $6.8M Series-A Financing

2018-05-02T01:29:45-05:00October 1st, 2014|

ROCHESTER, NY:  Adarza BioSystems, Inc. a leading next generation innovator in label-free, multiplex assays announced today that it has closed the final tranche of its Series-A financing bringing the total Series-A financing amount to $6.8 million. Proceeds from the financing will be used to launch its first 100-plex immunoassay product consumable and instrument and accelerate development of higher plex highly sensitive assays targeting a variety of biological analytes. Adarza’s Arrayed Imaging Reflectometry (AIR-StripTM) will bring an unprecedented combination of performance and workflow benefits with high sensitivity, broad dynamic range, precision and assay robustness to [...]

17 04, 2013

BioGenerator Investment Helps Adarza BioSystems Establish Operations in St. Louis

2018-05-02T01:29:45-05:00April 17th, 2013|

Life Science company expands presence to St. Louis ST. LOUIS, MO:  BioGenerator recently led syndication of investment in Adarza BioSystems, Inc., to support further commercialization of the company’s immunoassay products. As part of the investment, Adarza will conduct its primary business and product development in St. Louis as well as its manufacturing activities. Adarza is a next-generation multiplex immunoassay product company focused on applications in life science tools and the in vitro diagnostics markets. Multiplex technology allows researchers to explore the regulation of many different targets simultaneously. Adarza’s products and services utilize its proprietary [...]